‘I he ‘ēsiti ‘amino pē ‘e ua ‘i hono lōloá ., Ko e Vilon ko e peptide nounou taha ia 'oku 'iloa 'oku 'i ai 'a e ngaue fakapaiolosia .. 'Oku fakahaa'i 'e he fakatotolo 'oku 'i ai 'a e ngaahi ola malohi 'o e Vilon 'i he fakafepaki'i 'o e motu'a pea ko ha regulator malohi ia 'o e ngaue 'a e malu'i .. 'Oku 'i ai foki mo e fakamo'oni lelei 'oku tokoni 'a e Vilon ke fakatonutonu 'a e sisitemi vascular mo poupou'i 'a e hemostasis .. Kuo fakahaa'i 'e he Vilon ke fakasi'isi'i 'a e tupu mo e tupulaki 'o e ngaahi kafo 'oku hoko fakafokifā ., neongo ko hono fatongia ko ha adjuvant 'i he faito'o 'o e kanisaa . ('o fakafepaki'i 'a e ta'ofi .) kuo fakafehu‘ia .. Fakakatoa, 'Oku 'i ai ha kau taukave fefeka 'e ni'ihi 'a Vilon ., hange ko Dr .. Valatimili ʻAnisimovi, 'oku nau ongo'i ko e peptide ko ha fakafofonga geroprotective 'aonga ..
Fakahokohoko
Lisilikulutamate, faito'o mata angamaheni, 'Esiti lisikulutamiki
Fika CAS
45234-02-4
Fomula Molekula
K176H277N57O55S7.
Mamafa Molekula
257.30
Vilon Fakatotolo fekau'aki
'Oku fakahaa'i 'e he fakatotolo mei Lusia ko e Vilon ko ha regulator malohi 'o e chromatin 'a e fokotu'utu'u .. Na‘e ‘ilo ‘i ha ako ‘e taha ko e Vilon .:
• fakatupu ‘a e vete ‘o e chromatin .,
• fakatupu 'a e ngaahi founga fakatupu 'o fakafou 'i hono toe fakatupu 'o e ngaahi to'onga fakatupu 'o e ribosomal 'i he chromatin 'oku 'ikai ke fakatakamilo .,
• tukuange mai ‘a e ngaahi kēnisi kuo ta‘ofi ., mo e
• 'oku 'ikai ke ne fakatupu 'a e decondensation 'o e chromatin fakafa'unga pericentromeric .[1].nduces 'a e vete 'o e kolomatini,
Ko e ola kupesi 'o e ngaahi liliu 'oku fakatupu 'e Vilon ki he DNA ko e reactivation 'o e ngaahi genes 'oku kehe 'a e fakalongolongo .. 'I he fakalukufua ., chromatin 'oku ma'u ia 'i he taha 'o e lavea . (heterokolomatini) pe vete lavea . (ʻiukolomatini) ngaahi siteiti. ‘Oku ‘ikai lava ke ma‘u ‘a e heterochromatin ‘e he me‘angāue ‘okú ne liliu ‘a e ngaahi kēnisí ki he ngaahi polotiní pea ko ia ai ‘oku ngāue ‘a e ngaahi konga ‘o e selá .. Ko e ngaahi kēnisi ‘i he ngaahi vahefonua ko eni ‘o e DNA ‘oku ‘ikai pē ke ma‘u ia ki hono ngaohi ‘o e polotiní ..
'I he fakalukufua ., ‘oku tokoni ‘a e chromatin ke ne fakatonutonu ‘a e ngaahi kēnisi ‘oku ala ma‘u ki he tohí pea ko ia ai ko e founga ia ‘e taha ‘e lava ke ma‘u ai ‘e he ngaahi selo-kehekehe ‘a e ngaahi ngāue kehekehe pe ‘e lava ke ma‘u ‘e he ngaahi selo tatau ‘a e ngaahi ngāue kehekehe ‘i he faai mai ‘a e taimí .. Me'apango, chromatin condensation ko ha meʻa foki ia ʻoku hoko ko e ola ʻo e motuʻá mo e motuʻá pea ko e ʻuhinga ia ʻe taha ʻoku mole ai ʻetau ngaahi selá mo e ngaahi tisiú ʻi heʻetau motuʻá ..
Tatau mo 'ene ngaue 'i he lymphocytes ., Kuo fakahaa'i 'e Vilon ke faka'aonga'i 'a e interluekin-2 faka'ilonga 'i he ngaahi selo 'o e 'uto .[3]. 'Oku mahu'inga 'a e Interleukin-2 'i hono fakafekau'aki 'o e tali malu'i ki he ma'u 'e he microbial pea tokoni ke ta'ofi 'a e ngaahi tali 'o e autoimmune .. 'I hono faka'aonga'i 'o e lymphocytes mo e splenocytes lolotonga hono fakalahi 'o e malu'i fakanatula mei he ngaahi tali 'o e autoimmune ., ‘Oku fakafoki ‘e he Vilon ‘a e sisitemi malu‘í ki ha tu‘unga ‘oku toe mālohi ange pea ‘e a‘u nai ‘o ‘aonga ia ‘i hono fa‘u ‘a e ngaahi faito‘o ki he ngaahi mahaki ‘oku ‘ikai ke malu‘i ‘e he sinó ..
Tānaki atu ki hono malava ke ta'ofi 'a e ngaahi tali 'o e autoimmune ko e fatongia 'o e Vilon 'i he thymus .. 'Oku fakahaa'i 'e he fakatotolo 'i he ngaahi anga fakafonua 'o e thymus 'oku fakalahi 'e he Vilon 'a e tupulaki 'o e CD5 T-selo .. Ko e CD5 ko ha faka'ilonga ia 'o e ngaahi selo matu'otu'a T-tokoni pea pehe ki he cytotoxic CD8 T-selo .. 'Oku tokoni 'a e mu'omu'a ke fakatonutonu 'a e sisitemi malu'i mo ta'ofi 'a e ngaahi tali 'o e autoimmune ., lolotonga ia ko e fakamuimui tahá ko e taha ia ʻo e ngaahi selo fakafepakiʻi ʻo e fanga kiʻi meʻamoʻui ʻoku mālohi taha ʻi he sinó .[4].
Ko e meʻa mālié, 'Oku ngali 'oku reactivate pe 'e Vilon 'a e ngaahi ngaue malu'i 'o fakafou 'i he ngaahi to'onga fakatupu kuo fakalongolongo'i 'e he ngaahi liliu 'i he chromatin .. ‘Oku ‘ikai ke hā ngali ‘okú ne faka‘aonga‘i ‘a e ngaahi kēnisi ‘a ia ‘e fakanatula pē ke nau fakalongolongo ‘i he ngaahi sela ‘okú ne uesia .. Ko hono fakalea ʻe tahá ., ‘Oku ‘ikai ke liliu ‘e Vilon ‘a e ngaahi lymphocytes ki he ngaahi neurons ‘aki hono faka‘aonga‘i ‘a e ngaahi kēnisi ‘a ia ‘i he tu‘unga anga-mahení ‘e ‘ikai ke nau ngāue ‘i he ngaahi lymphocytes mo‘ui leleí .. Pe, 'oku 'asi mai 'a e peptide ke boost 'a e ngaue 'i he sisitemi malu'i lolotonga ia 'oku tokoni 'i he taimi tatau ke ta'ofi 'a e ngaahi tali 'o e autoimmune ..
Vilon mo e Kanisā .
Hange ko ia kuo fakahaa'i atu 'i 'olunga ., 'Oku tokoni 'a e Vilon ke fakasi'isi'i 'a e tupu 'a e kanisaa 'i he ngaahi sipinga 'o e mouse ., ‘a ia ko e founga ‘e taha ‘a ia ‘okú ne fakalōloa ai ‘a e ‘avalisi ‘o e mo‘uí .. 'Oku fakahaa'i 'e he ngaahi fakatotolo kehe 'oku 'ikai ngata pe 'i hono ta'ofi 'e Vilon 'a e ngaahi kafo mei he fa'u ., ka ‘okú ne ta‘ofi ‘enau tupú hili ‘enau ‘i aí .[5]. 'Oku fokotu'u mai 'e he me'a ni 'e lava ke fakatou hoko 'a e Vilon ko ha faito'o konatapu 'aonga 'i hono totonu 'o'ona ., pea pehē ki ha me‘a ‘e lava ke tānaki atu ki he ngaahi faito‘o kanisaa ‘oku lolotonga ‘i aí .. ‘I he kaha‘ú ., Mahalo ko e Vilon ko ha tānaki anga-maheni ia ki he meʻa kotoa pē mei he faitoʻo kemikale ki he faitoʻo ʻo e radiation mo e tafa ..
‘Ikai si‘i hifo ‘i he ako ‘e taha ., mei Lūsia ., ‘oku fepaki ia mo e fakamatala ‘oku pehē ‘e hoko nai ‘a e Vilon ko ha tokoni ‘aonga ki he faito‘o fakakemikalé .. 'Oku fakahaa'i 'e he ngaahi ngaue 'a e fakataha'i 'o e Vilon mo e palatini-fakava'e 'i he ngaahi fakafofonga 'o e chemotherapeutic 'oku palopalema kae 'ikai ko e synergistic .[6]. Me'apango, na‘e ngāue‘aki ‘e he ako ko ení ‘a e fa‘ahinga faito‘o fakakemikale pau pē ‘e taha pea na‘e fakangatangata pē hono lahí ., ko ia 'oku 'ikai lava ke fakalahi 'a e ngaahi ola .. 'Oku kei sio pe 'oku ola lelei pe 'a e Vilon ki he kanisaa 'iate ia pe pe 'e lava ke tanaki atu 'a e peptide ki he ngaahi founga faito'o kehe ke boost 'a e ola ..
Vilon mo e Motu'a .
Research in mice shows that subcutaneous administration of Vilon increases physical activity and endurance while helping to reduce the risk of cancer. These two effects resulted in longer lifespan in the treated mice, suggesting that Vilon may be a legitimate anti-aging peptide[7]. This is especially encouraging given that it produced no adverse effects in the mice following long-term administration.
Ko e meʻa mālié, the research shows that the earlier Vilon is administered, the greater its effects seem to be. Ko hono fakalea ʻe tahá ., giving Vilon to young mice enhances lifespan more than if Vilon is not administered until the mice are much older. This same effect was seen in early studies looking at crude thymic and pineal extracts given to mice to slow down aging[8]. The speculation is that Vilon and similar peptides, when administered late in life, can reverse senescence in existing cells but can obviously do nothing for cells that have already been eliminated through apoptosis. By administering Vilon 20mg early in life, cells get the greatest amount of protection and so turnover is slowed down. The result is that more cells stay healthy for longer periods of time, slowing the need to replace them and preserving limited stem cell lines.
Vilon’s anti-aging effects seem to extend to GI function as well, where the peptide has been shown to improve the activity of certain enzymes in the Gi tracts of older mice. The peptide also appears to improve barrier function, thus reducing the incidence of leaky gut, enhancing disease resistance, and improving the overall health of the GI tract in older mice[9]. Research shows that Vilon thereby helps to improve glucose and glycine absorption in the small intestine of older rats[10]. These features of Vilon may help to maintain nutrient extraction with age, thereby improving overall well-being and perhaps enhancing longevity.
Dr. Vladimir N. ʻAnisimovi, who has been researching aging and cancer development since the 1970s, points out that the thymus is one of two glands (the other being the pineal gland) that plays an important role in regulating aging. The healthier the thymus is, the healthier we are as individuals. Of course, Vilon is a thymic peptide and affects cells, like lymphocytes, that are produced in and mature in the thymus. Dr. Anisimov is a staunch advocate for using peptide bioregulators in the prevention of cancer[11]. He is a close colleague of Dr. Vladimir Khavinson.
Vilon 'i he Loto mo e Fatu .
Ko e ola 'o e Vilon 'i he vasculature kuo si'isi'i ange hono ako lelei ., ka ‘oku ‘i ai ‘a e ngāue ‘e ni‘ihi ‘oku fokotu‘u mai ai ‘e ‘i ai nai hano ola ‘aonga .. 'Oku fakahaa'i 'e he fakatotolo 'i he fanga ki'i mice 'oku liliu 'e he Vilon 'a e fakahaa'i 'o e lahi ange 'i he 100. 36 ngaahi kēnisi kehekehe ‘i loto ‘i he lotó .. Ka fakataha'i mo e 'Epitaloni ., 'oku puna 'a e fika ko 'eni ki he 10. 144 ngaahi kēnisi[12]. Ko e ngaahi me‘a ko eni kuo ma‘ú ‘oku fokotu‘u mai ai ‘oku ., ʻi he siʻisiʻi tahá, 'Oku ma'u 'e Vilon 'a e malava ke liliu 'a e ngaahi founga 'o e fakahaa'i 'o e gene 'i he sisitemi cardiovascular ., ko ha mo‘oni‘i me‘a ‘e lava ke ne fakalelei‘i ‘a e ngāue ‘a e hemodynamic ..
Ko hono mo'oni, fakatotolo ‘i he ngaahi fatú, ngaahi 'okani vascular ma'olunga, 'oku fakahaa'i 'e he Vilon 'oku fakasi'isi'i 'a e ngaahi tokanga 'o e liliu 'o e tupulaki 'o e me'a-beta .(1) pea ko ia ko e permeability 'o e ngaahi ipu si'isi'i .. Ko e ola 'o e kupenga ko e fakalelei'i 'o e hemostasis lolotonga 'a e ta'elavame'a 'a e fatú ., fokotu'u atu 'oku fai 'e Vilon ., Ko hono mo'oni, 'oku 'i ai ha ola lelei ki he sisitemi vascular .[13].
Tanaki atu, 'oku fakahaa'i 'e he fakatotolo 'i he kau mahaki matu'otu'a 'oku nau ma'u 'a e suka 'e lava ke tokoni 'a e Vilon ke fakalelei'i 'a e coagulation 'aki hono fakalahi 'a e ngaahi tu'unga 'o e anticoagulants fakanatula antithrombin III mo e polotini C lolotonga ia 'oku ne toe faka'ai'ai 'a e fibrinolysis .[14]. Ko hono olá ko e si‘isi‘i ange ‘a e ngaahi fo‘i toto ‘i ha kakai ‘oku nau faingofua ke fo‘i ‘a e totó pea mo e ngaahi nunu‘a mamafa ‘oku hoko atu aí .. ‘Oku toe poupou‘i ‘e he me‘á ni ‘a e fakakaukau ‘oku fakahoko ‘e Vilon ha fatongia mahu‘inga ‘i hono fakatonutonu ‘a e sisitemi vascular ..
COA
HPLC
MS
Ngaahi Fakatokanga ki he Kupu/Tohi
Ko e taumu‘a ‘o hono lave ki he fakamatala ‘a e saienisi mo e palōfesá ke fakamo‘oni‘i ., fakatokanga'i mo fakahikihiki'i 'a e ngaue fakalakalaka faka'aufuli kuo fai ke fakahoko 'a e fakatotolo peptide ko 'eni .. ‘Oku ‘ikai ke poupou‘i pe taukave‘i ‘e he saienisí ‘i ha fa‘ahinga founga ‘a e fakataú ., fakatau atu pe ngaue'aki 'a e koloa ko 'eni 'i ha fa'ahinga 'uhinga pe ., pea 'oku 'ikai ha fekau'aki pe fekau'aki 'a e MOL Changes ., fakahu'unga pe kehe, mo e saienisi ..
fakatokanga
Ko e ngaahi koloa ko 'eni 'oku fakataumu'a ia ki he ngaahi taumu'a fakasaienisi pe ki he fakatotolo 'i he vitro pea 'oku 'ikai ke faka'aonga'i ia ki he tangata ., monumanu pe ngaahi 'ahi'ahi ta'efaka'ulungaanga, fakatotolo 'i he vitro (Faka-Latina: 'i he sio'ata) 'oku fakahoko 'i he vitro .. These products are not drugs and are not approved by the Food and Drug Administration in any country for the prevention, treatment or cure of any medical condition, disease or illness. The introduction of this product into humans or animals in any form is strictly prohibited by law.





